1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis program delivers comprehensive support to family caregivers and care partners of individuals living with Alzheimer's and related dementias (ADRD) across North Carolina.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Organizations able to execute the delivery of the Project C. A. R. E. program to family caregivers and care partners of individuals living with ADRD serving all 100 North Carolina counties. Confirm the full requirements in the official notice before applying.
Applications for Project C.A.R.E. (Caregiver Alternatives to Running on Empty) are due October 30, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Project C.A.R.E. (Caregiver Alternatives to Running on Empty) is funded by North Carolina Division of Aging. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Seven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read articleARPA-H awarded $144M across 7 research teams to run the first clinical trials treating aging as a condition — not a disease. How PROSPR reshapes longevity funding and what grant seekers in biotech, academia, and health tech should know.
Read article